| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
23,910,000 |
| Market
Cap: |
2.49(B) |
| Last
Volume: |
121,225 |
Avg
Vol: |
187,214 |
| 52
Week Range: |
$81.08 - $194.07 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
S&P SMALLCAP 600 |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 789 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile ICU Medical is an infusion therapy company. Co. has four product lines: Infusion Consumables, which include Clave™ needlefree products, SwabCap and SwabTip disinfecting caps, ClearGuard HD antimicrobial barrier caps for hemodialysis catheters and Tego™ hemodialysis connector used to cap and protect hemodialysis central venous catheter hubs; Infusion Systems, which provide infusion pumps, dedicated IV sets, software and other services; IV Solutions, which provide a supply of IV solutions, irrigation and nutritionals; and Critical Care, which helps clinicians get real-time access to patients' hemodynamic and cardiac status with a portfolio of monitoring systems and sensors and catheters.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
1,734,283 |
1,736,012 |
1,803,056 |
1,805,820 |
| Total Sell Value |
$183,912,843 |
$184,065,039 |
$196,046,715 |
$196,566,564 |
| Total People Sold |
8 |
8 |
9 |
9 |
| Total Sell Transactions |
14 |
15 |
19 |
23 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Woolson Daniel |
VP, GM-Infusion Capital |
• – – |
2019-02-13 |
4 |
D |
$0.00 |
$0 |
D/D |
(688) |
1,594 |
|
- |
|
| Woolson Daniel |
VP, GM-Infusion Capital |
• – – |
2019-02-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
2,282 |
2,282 |
|
- |
|
| Mcgrody Kevin J |
Controller |
• – – |
2019-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
290 |
2,909 |
|
- |
|
| Mcgrody Kevin J |
Controller |
• – – |
2019-02-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(119) |
2,619 |
|
- |
|
| Sanzone Virginia Ruth |
VP, General Counsel |
• – – |
2019-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,157 |
2,099 |
|
- |
|
| Sanzone Virginia Ruth |
VP, General Counsel |
• – – |
2019-02-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(425) |
942 |
|
- |
|
| Jain Vivek |
Chairman and CEO |
• • – |
2019-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,759 |
50,584 |
|
- |
|
| Jain Vivek |
Chairman and CEO |
• • – |
2019-02-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(1,318) |
46,825 |
|
- |
|
| Voigtlander Christian B. |
Chief Operating Officer |
• – – |
2019-02-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(423) |
2,943 |
|
- |
|
| Voigtlander Christian B. |
Chief Operating Officer |
• – – |
2019-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,157 |
3,366 |
|
- |
|
| Mccall Thomas D |
Vice President and Genl Mgr. |
• – – |
2019-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
679 |
2,610 |
|
- |
|
| Mccall Thomas D |
Vice President and Genl Mgr. |
• – – |
2019-02-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(260) |
1,931 |
|
- |
|
| Brummett Burcar Alison |
Vice President and Genl Mgr. |
• – – |
2019-02-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(445) |
770 |
|
- |
|
| Brummett Burcar Alison |
Vice President and Genl Mgr. |
• – – |
2019-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,215 |
1,215 |
|
- |
|
| Lamb Scott E |
Chief Financial Officer, |
• – – |
2019-02-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
914 |
8,180 |
|
- |
|
| Lamb Scott E |
Chief Financial Officer, |
• – – |
2019-02-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(339) |
7,266 |
|
- |
|
| Swinney Robert S |
Director |
– • – |
2019-01-28 |
4 |
AS |
$242.19 |
$363,285 |
D/D |
(1,500) |
18,040 |
|
- |
|
| Swinney Robert S |
Director |
– • – |
2019-01-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
19,540 |
|
- |
|
| Lopez George A |
Director |
– • • |
2018-12-18 |
4 |
GD |
$0.00 |
$0 |
D/D |
13,784 |
348,864 |
|
- |
|
| Mcgrody Kevin J |
Controller |
• – – |
2018-12-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
223 |
2,738 |
|
- |
|
| Mcgrody Kevin J |
Controller |
• – – |
2018-12-07 |
4 |
D |
$0.00 |
$0 |
D/D |
(111) |
2,515 |
|
- |
|
| Pfizer Manufacturing Llc |
See Note (1) |
– – – |
2018-11-15 |
4 |
S |
$209.25 |
$523,125,000 |
I/I |
(2,500,000) |
0 |
|
- |
|
| Mcgrody Kevin J |
Controller |
• – – |
2018-09-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
571 |
2,626 |
|
- |
|
| Mcgrody Kevin J |
Controller |
• – – |
2018-09-01 |
4 |
D |
$0.00 |
$0 |
D/D |
(204) |
2,055 |
|
- |
|
| Sanzone Virginia Ruth |
VP, General Counsel |
• – – |
2018-08-28 |
4 |
S |
$303.12 |
$238,555 |
D/D |
(787) |
1,367 |
|
- |
|
1484 Records found
|
|
Page 16 of 60 |
|
|
2.28 (2.15%) 
